Literature DB >> 18055833

The oscillatory potentials of the dark-adapted electroretinogram in retinopathy of prematurity.

James D Akula1, Julie A Mocko, Anne Moskowitz, Ronald M Hansen, Anne B Fulton.   

Abstract

PURPOSE: To study the development of the electroretinographic (ERG) oscillatory potentials (OPs) in two rat models of ROP and in human subjects with a history of ROP.
METHODS: Sprague-Dawley rats (n = 36) were studied longitudinally. Rat models of ROP were induced, either by exposure to alternating 50%/10% oxygen (50/10 model) from postnatal day (P) 0 to P14 or by exposure to 75% oxygen (75 model) from P7 to P14. Control rats were reared in room air. Infant and adult human subjects with and without a history of ROP (n = 91) were also studied. Dark-adapted ERGs were recorded and filtered to demonstrate the OPs. Discreet Fourier transform (DFT) allowed evaluation of the OP power spectrum. OP energy (E), dominant frequency (F(peak)), and sensitivity (log i(1/2)) were evaluated.
RESULTS: In 50/10 model rats, E was low compared with that in the 75 model rats and control animals. F(peak) (approximately 95 Hz) did not vary with age or group. Intriguingly, log i(1/2) in 75 model rats was greater than that in controls or 50/10 model rats. Human adults with a history of ROP had lower-energy OPs than did the control adults, but infants with a history of ROP had higher-energy OPs than did the control infants. F(peak) was lower (approximately 120 Hz) in infants than in adults (approximately 130 Hz). ROP did not affect log i(1/2) in humans.
CONCLUSIONS: Differences between OPs in healthy rats and healthy humans were substantial, suggesting that OPs in rat models of ROP are unlikely to provide insight into the effects of ROP on human OPs. Indeed, neither ROP model studied showed a pattern of effects similar to that in human ROP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055833      PMCID: PMC2238706          DOI: 10.1167/iovs.07-0881

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  61 in total

1.  Standard for clinical electroretinography (2004 update).

Authors:  Michael F Marmor; Graham E Holder; Mathias W Seeliger; Shuichi Yamamoto
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

2.  Development of the prenatal rat retina.

Authors:  T Kuwabara; T A Weidman
Journal:  Invest Ophthalmol       Date:  1974-10

3.  Cell differentiation in the retina of the mouse.

Authors:  R W Young
Journal:  Anat Rec       Date:  1985-06

4.  The oscillatory waves of the primate electroretinogram.

Authors:  T E Ogden
Journal:  Vision Res       Date:  1973-06       Impact factor: 1.886

Review 5.  The eclectroretinogram: its components and their origins.

Authors:  K T Brown
Journal:  Vision Res       Date:  1968-06       Impact factor: 1.886

6.  Development of the rat retina.

Authors:  T A Weidman; T Kuwabara
Journal:  Invest Ophthalmol       Date:  1969-02

7.  Origin of the oscillatory potentials in the primate retina.

Authors:  H Heynen; L Wachtmeister; D van Norren
Journal:  Vision Res       Date:  1985       Impact factor: 1.886

8.  Origins of the electroretinogram oscillatory potentials in the rabbit retina.

Authors:  Cun-Jian Dong; Peter Agey; William A Hare
Journal:  Vis Neurosci       Date:  2004 Jul-Aug       Impact factor: 3.241

9.  Modulation of the components of the rat dark-adapted electroretinogram by the three subtypes of GABA receptors.

Authors:  Anna Möller; Thor Eysteinsson
Journal:  Vis Neurosci       Date:  2003 Sep-Oct       Impact factor: 3.241

Review 10.  Oscillatory potentials. History, techniques and potential use in the evaluation of disturbances of retinal circulation.

Authors:  P Speros; J Price
Journal:  Surv Ophthalmol       Date:  1981 Jan-Feb       Impact factor: 6.048

View more
  41 in total

1.  A novel role for the immunoproteasome in retinal function.

Authors:  Stacy A Hussong; Heidi Roehrich; Rebecca J Kapphahn; Marcela Maldonado; Machelle T Pardue; Deborah A Ferrington
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-09       Impact factor: 4.799

2.  Signal processing techniques for oscillatory potential extraction in the electroretinogram: automated highpass cutoff frequency estimation.

Authors:  John Meklenburg; Edward A Clancy; Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2012-07-10       Impact factor: 2.379

3.  Protective role of somatostatin receptor 2 against retinal degeneration in response to hypoxia.

Authors:  Massimo Dal Monte; Valentina Latina; Elena Cupisti; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-07       Impact factor: 3.000

4.  Long-term effects of retinopathy of prematurity (ROP) on rod and rod-driven function.

Authors:  Maureen E Harris; Anne Moskowitz; Anne B Fulton; Ronald M Hansen
Journal:  Doc Ophthalmol       Date:  2010-11-03       Impact factor: 2.379

Review 5.  The neurovascular retina in retinopathy of prematurity.

Authors:  Anne B Fulton; Ronald M Hansen; Anne Moskowitz; James D Akula
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

6.  Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy.

Authors:  Andreas Stahl; Jing Chen; Przemyslaw Sapieha; Molly R Seaward; Nathan M Krah; Roberta J Dennison; Tara Favazza; Felicitas Bucher; Chatarina Löfqvist; Huy Ong; Ann Hellström; Sylvain Chemtob; James D Akula; Lois E H Smith
Journal:  Am J Pathol       Date:  2010-11-05       Impact factor: 4.307

7.  Vigabatrin can enhance electroretinographic responses in pigmented and albino rats.

Authors:  James D Akula; Emily R Noonan; Alessia Di Nardo; Tara L Favazza; Nan Zhang; Mustafa Sahin; Ronald M Hansen; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2015-03-12       Impact factor: 2.379

8.  Rod and rod-driven function in achromatopsia and blue cone monochromatism.

Authors:  Anne Moskowitz; Ronald M Hansen; James D Akula; Susan E Eklund; Anne B Fulton
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-29       Impact factor: 4.799

9.  Broad spectrum antiangiogenic treatment for ocular neovascular diseases.

Authors:  Ofra Benny; Kei Nakai; Takeru Yoshimura; Lauren Bazinet; James D Akula; Shintaro Nakao; Ali Hafezi-Moghadam; Dipak Panigrahy; Pouya Pakneshan; Robert J D'Amato
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

10.  Inhibition of the adrenomedullin/nitric oxide signaling pathway in early diabetic retinopathy.

Authors:  Jan J Blom; Thomas J Giove; Tara L Favazza; James D Akula; William D Eldred
Journal:  J Ocul Biol Dis Infor       Date:  2012-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.